上峯水泥(000672.SZ):擬註冊及發行超短期融資券和中期票據
格隆匯6月30日丨上峯水泥(000672.SZ)公佈,公司於2025年6月30日上午10:00時以通訊表決方式召開第十一屆董事會第三次會議,審議通過了《關於擬註冊及發行超短期融資券和中期票據的議案》,為滿足公司經營發展需要,拓寬融資渠道,優化債務結構,降低資金成本,公司擬向中國銀行間市場交易商協會申請註冊發行不超過人民幣10億元(含10億元)的超短期融資券和不超過人民幣10億元(含10億元)的中期票據,採用分期發行的方式,具體發行規模根據在中國銀行間市場交易商協會最終註冊的金額、資金需求和市場情況確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.